NEWS
最新消息
-
News2025/12/10Elixiron Immunotherapeutics Pre-Listing Investor Conference
-
Statement Clarifying2025/12/04The Company Statement Clarifying Recent Market Speculations
-
Media2025/09/18Elixiron Targets T-Cell Exhaustion with 2026 Phase I Trial
-
Media2025/07/29Japan, Korea, and Taiwan Spotlight Innovative Alzheimer’s Therapies — Elixiron’s Enrupatinib Earns High Praise at International Forum, Pioneering a New Immunotherapy Option
-
Event2025/07/01Bio Asia Taiwan 2025 Corporate Presentation Highlights: A New Hope for Alzheimer’s Patients — Innovative Therapy from Elixiron Biotherapeutics
-
Media2025/06/12Immunotherapy Rising Star Elixiron Raises NT$1 Billion, Secures Rakuten Investment, and Targets Q4 Emerging Stock Board Listing
-
Media2025/05/18FISS 2025 Brings Together Leading Experts to Boost Taiwan’s Immunotherapy Research Capacity
-
Media2024/11/28Taiwan's new drug research and development is accelerating! Anlixirong won the "2024 Moderna Taiwan mRNA Foresight Innovation Award", breaking through the bottleneck of cancer treatment, and vitiligo immune drug entered the second phase of clinical trials
-
Media2024/11/13Elixiron Biotherapeutics Wins Emerging Company of the Year at MIT Technology Review China Life Science Competition
-
Media2024/10/24Why Elixiron Biotherapeutics Secured Funding from Bill Gates — Chairman Hung-Kai Chen Reveals the Key: Precision Medicine, Cross-Disciplinary Applications, and Accelerated Innovation
-
Research2024/08/30Elixiron Immunotherapeutics to Initiate Phase 2 Clinical Trial of Innovative Alzheimer's Drug EI-1071 at Taipei Veterans General Hospital
-
Media2024/07/29Elixiron’s Precision Immunotherapy Wins Outstanding Startup Award
